- Home
- BLND vs MNPR Comparison
BLND vs MNPR Comparison
Compare BLND & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLND | MNPR |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.9M | 368.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BLND | MNPR |
|---|---|---|
| Price | $1.69 | $64.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $4.13 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 3.1M | 125.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,585,000.00 | N/A |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.18 | $29.18 |
| 52 Week High | $4.49 | $105.00 |
Technical Indicators
Market Signals| Indicator | BLND | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 62.89 |
| Support Level | $1.56 | $64.25 |
| Resistance Level | $1.89 | $67.19 |
| Average True Range (ATR) | 0.12 | 3.16 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 44.83 | 88.45 |
Price Performance
Historical ComparisonAbout BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.